GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

Rating:
Mkt Outperform
ALNY
up 1,257.05 %

Alnylam Pharmaceuticals, Inc. (ALNY) rated Mkt Outperform by JMP Securities

Posted on: Friday,  Feb 8, 2013  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 02/08/2013. Previously JMP Securities rated Mkt Outperform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
on 12/15/2011., when the stock price was $7.73. Since then, Alnylam Pharmaceuticals, Inc. has gained 1257.05% as of 01/22/2016's recent price of $104.90.
If you would have followed the previous JMP Securities's recommendation on ALNY, you would have gained 1257.05% of your investment in 1499 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/8/2013 8:25 AM Buy
None
24.82
as of 12/13/2013
1 Week down  -5.65 %
1 Month up  11.75 %
3 Months up  7.78 %
1 YTD up  225.58 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/10/2012 10:25 AM Buy
None
11.78 17.00
12/15/2011 11:25 AM Buy
None
7.73 12.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy